CorMedix Inc.
CRMDHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, CorMedix Inc. (CRMD) is listed under Biotechnology. The company carries a $611.9M market cap, placing it firmly in the small-cap category. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Market Cap
$611.9M
Beta
1.41
P/E (TTM)
3.83
P/E (Fwd)
22.43
EPS (TTM)
$2.05
EPS (Fwd)
$0.35
ROE
54.9%
ROA
24.6%
Cash
$256.7M
Total Debt
$147.5M
Free CF
$178.1M
52W Change
-29.7%
Annual Financials
Cash vs Debt
Where CRMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRMD finished 5.38% below its 150-day moving average ($7.80) and 4.65% below its 200-day moving average ($7.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRMD overbought or oversold?
At the October 20, 2026 close, CRMD's RSI(14) was 31.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $256.7M in cash and $147.5M in debt, CRMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $178.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 54.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 24.6% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $191K to $311.7M.
As with any equity investment, CRMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing CRMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.